Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed undifferentiated nasopharyngeal cancer (UNPC)~  * Locoregionally advanced disease~    * T2b, N1 (greater than 3 cm) or N2~   * T3, N1 (greater than 3 cm) or N2~   * T4, N1 (greater than 3 cm) or N2~   * Any T, N3~ * No squamous cell histology~* At least 1 unidimensionally measurable target lesion~  * At least 20 mm by conventional techniques OR~ * At least 10 mm by spiral CT scan~* No evidence of distant metastases~* No signs or symptoms of CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 15 to 70~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 2,000/mm\^3~* Platelet count at least 150,000/mm\^3~* Hemoglobin at least 12 g/dL~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST/ALT no greater than 2.5 times ULN~Renal:~* Creatinine clearance at least 70 mL/min~* Calcium normal~Cardiovascular:~* No hypotension or hypertension requiring therapy~* No prior myocardial infraction~* No pre-existing uncontrolled cardiac disease~* No signs of cardiac failure~* No rhythm disturbances requiring medication~Other:~* No sensory neuropathy grade 2 or greater unless due to cranial nerve~* No uncontrolled infections~* No sensitivity to aminothiol compounds~* No other malignancy within the past 5 years except adequately controlled carcinoma in situ of the cervix or basal cell or squamous cell skin cancer~* No psychological, familial, sociological, or geographical condition that would preclude study~* Fertile patients must use effective contraception during and for 3 months after study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy~Chemotherapy:~* No prior chemotherapy for UNPC~Endocrine therapy:~* No concurrent hormonal therapy except corticosteroids for antiemetic prophylaxis~Radiotherapy:~* No prior radiotherapy for UNPC~Surgery:~* No prior surgery for UNPC except cervical lymphadenectomy~Other:~* At least 1 month since prior investigational agent~* No other concurrent anticancer drugs

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).